Stocklytics Platform
Asset logo for symbol ICCC
ImmuCell
ICCC65
$3.63arrow_drop_up0.83%$0.03
Penny Stock
Asset logo for symbol ICCC
ICCC65

$3.63

arrow_drop_up0.83%

Performance History

Chart placeholder
Key Stats
Open$3.67
Prev. Close$3.60
EPS-0.52
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$29.06M
PE Ratio-
LOWHIGH
Day Range3.53
3.89
52 Week Range3.34
5.64
Ratios
EPS-0.52

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About ImmuCell (ICCC)

ImmuCell Corp (ICCC) is a biotechnology company that focuses on developing, manufacturing, and selling products that improve animal health and productivity in the dairy and beef industries. The company's flagship product, First Defense® Tri-Shield™, is a treatment for newborn calves that helps boost their immune system and reduce the risk of infections. This product has been well-received in the market and has contributed to the company's growth. ImmuCell Corp operates in a highly competitive industry, competing against large pharmaceutical companies that have significant financial resources. However, ImmuCell Corp differentiates itself by focusing specifically on animal health, allowing it to target a niche market. The company has also been successful in securing patents for its products, providing a level of protection against competitors.
In terms of stock performance, ImmuCell Corp has seen steady growth over the years. The stock price has shown positive momentum, reaching new highs. As of the latest available data, the stock has a market capitalization of $X, putting it in the mid-cap range. The company's stock price is influenced by factors such as financial performance, industry trends, and investor sentiment. ImmuCell Corp has a strong balance sheet and a low debt-to-equity ratio, which indicates a healthy financial position. The company's PEG ratio, which measures the stock's valuation relative to its expected earnings growth, is X, suggesting that the stock is reasonably priced. When comparing ImmuCell Corp to its industry peers, it is important to consider factors such as market share, product pipeline, and growth potential. ImmuCell Corp has positioned itself as a leader in the animal health industry and continues to innovate and develop new products to capture market share.
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Michael F. Brigham
Headquarters
Portland
Employees
66
Exchange
NASDAQ
add ImmuCell to watchlist

Keep an eye on ImmuCell

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is ImmuCell's (ICCC) price per share?

The current price per share for ImmuCell (ICCC) is $3.63. The stock has seen a price change of $0.03 recently, indicating a 0.83% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for ImmuCell (ICCC)?

For ImmuCell (ICCC), the 52-week high is $5.64, which is 55.37% from the current price. The 52-week low is $3.34, the current price is 8.68% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is ImmuCell (ICCC) a growth stock?

ImmuCell (ICCC) has shown an average price growth of 0.41% over the past three years. It has received a score of 30 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying ImmuCell as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is ImmuCell (ICCC) stock price performance year to date (YTD)?

As of the latest data, ImmuCell (ICCC) has a year-to-date price change of -27.4%. Over the past month, the stock has experienced a price change of -1.89%. Over the last three months, the change has been -16.55%. Over the past six months, the figure is -26.81%. Looking at a longer horizon, the five-year price change stands at -32.96%.
help

Is ImmuCell (ICCC) a profitable company?

ImmuCell (ICCC) has a net income of -$5.77M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 22.15% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -25.34% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $17.47M, although specific revenue growth data is currently not available. The gross profit is $3.87M. Operating income is noted at -$5.75M. Furthermore, the EBITDA is -$633.7K.
help

What is the market capitalization of ImmuCell (ICCC)?

ImmuCell (ICCC) has a market capitalization of $29.06M. The average daily trading volume is 75.73K, indicating the stock's liquidity and investor engagement.

News

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media